12:00 AM
Nov 11, 2013
 |  BC Week In Review  |  Company News  |  Deals

Evotec, J&J deal

Evotec partnered with the Johnson & Johnson's Janssen Biotech Inc. subsidiary to identify new targets and compounds to treat Alzheimer's disease. Under the TargetAD collaboration, Janssen will fund Evotec's research costs and will have the exclusive option to license targets and compounds from Evotec's TargetAD database. The database comprises potential AD...

Read the full 234 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >